Therapeutic cleavage of IgG is dangerous in humans

Trends in Immunology

Volumn 29, Issue 8, 2008, Pages 353-354

  Lutz, Hans U ^a   Fumia, Sandra ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; AFELIMOMAB; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C3B; IMMUNOGLOBULIN FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; PLASMA PROTEIN; PROTEINASE;

ANTIBODY STRUCTURE; ANTIGEN ANTIBODY COMPLEX; AUTOIMMUNE DISEASE; HUMAN; LETTER; NONHUMAN; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIGEN-ANTIBODY COMPLEX; AUTOANTIBODIES; AUTOIMMUNE DISEASES; BACTERIAL PROTEINS; COMPLEMENT ACTIVATION; COMPLEMENT C3; HUMANS; IMMUNOGLOBULIN G; PEPTIDE HYDROLASES;

EID: 47749096680     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2008.04.009     Document Type: Letter

References (12)

1. Nandakumar K.S., and Holmdahl R. Therapeutic cleavage of IgG: new avenues for treating inflammation. Trends Immunol. 29 (2008) 173-178
2. Nandakumar K.S., et al. Blocking of experimental arthritis by cleavage of IgG antibodies in vivo. Arthritis Rheum. 56 (2007) 3253-3260
3. Terness P.I., et al. Immunosuppressive anti-immunoglobulin autoantibodies: specificity, gene structure and function in health and disease. Cell. Mol. Biol. 48 (2002) 271-278
4. 2 from the circulation. Eur. J. Immunol. 25 (1995) 3128-3133
5. 2-containing immune complexes together with anti-hinge natural antibodies stimulate complement amplification in vitro and in vivo. Mol. Immunol. 45 (2008) 2951-2961
6. Lutz H.U., and Jelezarova E. Complement amplification revisited. Mol. Immunol. 43 (2006) 2-12
7. Baici A., et al. Kinetics of the different susceptibilities of the four human immunoglobulin G subclasses to proteolysis by human lysosomal elastase. Scand. J. Immunol. 12 (1980) 41-50
8. Lutz H.U., et al. Opinion paper: stimulation of complement amplification or activation of the alternative pathway of complement?. Mol. Immunol. 44 (2007) 3862-3865
9. 2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit. Care Med. 32 (2004) 2173-2182
10. Marshall J.C. Such stuff as dreams are made on: mediator-directed therapy in sepsis. Nat. Rev. Drug Discov. 2 (2003) 391-405
11. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 349 (1997) 1429-1435
12. Dietrich H. Report on the experience in the treatment of septic diseases with Gamma-Venin. Dtsch. Med. J. 17 (1966) 709-710